CCR5 and Hepatic fibrosis: Cenicriviroc (CVC), a dual CCR2/CCR5 antagonist, exemplifies the efficacy of this approach by simultaneously reducing pro-inflammatory monocyte/macrophage activity and HSC-mediated fibrogenesis [171,172], as evidenced by clinical trials such as the CENTAUR phase 2b trial (NCT02217475), which demonstrated significant improvements in liver fibrosis and markers of liver injury [173].